ECSP22050936A - Compuestos tric?clicos sustituidos - Google Patents

Compuestos tric?clicos sustituidos

Info

Publication number
ECSP22050936A
ECSP22050936A ECSENADI202250936A ECDI202250936A ECSP22050936A EC SP22050936 A ECSP22050936 A EC SP22050936A EC SENADI202250936 A ECSENADI202250936 A EC SENADI202250936A EC DI202250936 A ECDI202250936 A EC DI202250936A EC SP22050936 A ECSP22050936 A EC SP22050936A
Authority
EC
Ecuador
Prior art keywords
compound
formula
tricyclic compounds
rasopathies
infectious
Prior art date
Application number
ECSENADI202250936A
Other languages
English (en)
Inventor
Manojkumar Shukla
Dagadu Dube
Nilesh Khedkar
Pradip Wagh
Venkata Palle
Samiron Phukan
Ganesh Kakade
Sudhakar Balgude
Milind Sindkhedkar
Sachin Sethi
Rajender Kumar Kamboj
Vikas Tambe
Prathap Nair
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of ECSP22050936A publication Critical patent/ECSP22050936A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se divulgan compuestos de f?rmula general (I), su forma tautom?rica, su estereois?mero, su sal farmac?uticamente aceptable, su polimorfo o solvato del mismo, en donde, el anillo A, de R1 a R5, X, Y, m, y n son como se definen en el presente documento, para su uso como inhibidores de SOS1 en el tratamiento de enfermedades o trastornos proliferativos infecciosos y rasopat?as. Tambi?n se divulgan m?todos para sintetizar el compuesto de f?rmula I, composiciones farmac?uticas que contienen el compuesto de f?rmula I, un m?todo para el tratamiento de enfermedades o trastornos proliferativos, infecciosos o rasopat?as, por ejemplo, un c?ncer, administrando dicho compuesto y combinaciones del compuesto de f?rmula I con otros principios activos.
ECSENADI202250936A 2019-11-29 2022-06-28 Compuestos tric?clicos sustituidos ECSP22050936A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921049157 2019-11-29
IN202021035414 2020-08-17

Publications (1)

Publication Number Publication Date
ECSP22050936A true ECSP22050936A (es) 2022-07-29

Family

ID=73856201

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202250936A ECSP22050936A (es) 2019-11-29 2022-06-28 Compuestos tric?clicos sustituidos

Country Status (29)

Country Link
US (1) US12435066B2 (es)
EP (1) EP4065575B1 (es)
JP (1) JP7629922B2 (es)
KR (1) KR20220110241A (es)
CN (1) CN114746411B (es)
AU (1) AU2020393205A1 (es)
BR (1) BR112022010383A2 (es)
CA (1) CA3154914A1 (es)
CL (1) CL2022001392A1 (es)
CO (1) CO2022008997A2 (es)
CR (1) CR20220312A (es)
DK (1) DK4065575T3 (es)
EC (1) ECSP22050936A (es)
ES (1) ES2982576T3 (es)
FI (1) FI4065575T3 (es)
HR (1) HRP20240547T1 (es)
HU (1) HUE066732T2 (es)
IL (1) IL292721A (es)
LT (1) LT4065575T (es)
MX (1) MX2022006475A (es)
PE (1) PE20221336A1 (es)
PH (1) PH12022551014A1 (es)
PL (1) PL4065575T3 (es)
PT (1) PT4065575T (es)
RS (1) RS65526B1 (es)
SI (1) SI4065575T1 (es)
SM (1) SMT202400273T1 (es)
WO (1) WO2021105960A1 (es)
ZA (1) ZA202206253B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249475A1 (zh) * 2020-06-10 2021-12-16 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
AU2021345111B2 (en) 2020-09-15 2025-11-27 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
CA3203205A1 (en) * 2021-01-19 2022-07-28 Mandar Ramesh Bhonde Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
US20240109891A1 (en) * 2021-03-02 2024-04-04 Viva Star Biosciences (Suzhou) Co., Ltd. Novel substituted tricyclic aza-heterocycles as sos1 inhibitors
AU2022250712A1 (en) 2021-03-31 2023-10-05 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
WO2022222875A1 (zh) * 2021-04-19 2022-10-27 昆药集团股份有限公司 一种苯并嘧啶三环衍生物及其制备方法和应用
CN115490699B (zh) * 2021-06-19 2024-08-09 成都海博为药业有限公司 一种稠环化合物及其药物组合物和用途
WO2023287730A1 (en) * 2021-07-13 2023-01-19 Recurium Ip Holdings, Llc Tricyclic compounds
CN115677699B (zh) * 2021-07-23 2024-11-22 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
US20240382475A1 (en) * 2021-08-30 2024-11-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Quinazoline Derivative, Or Preparation Method Therefor And Use Thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
KR20240122545A (ko) 2021-12-17 2024-08-12 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 항종양 활성을 갖는 헤테로고리 화합물 및 그 용도
CN116425796A (zh) * 2022-01-12 2023-07-14 如东凌达生物医药科技有限公司 一类嘧啶并杂环类化合物、制备方法和用途
US20250154147A1 (en) 2022-01-14 2025-05-15 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
CA3249536A1 (en) * 2022-01-21 2023-07-27 Foshan Ionova Biotherapeutics Co., Inc. Fused heterocyclic compounds used as RAS signaling modulators
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
GB202203976D0 (en) 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN116969944A (zh) * 2022-08-02 2023-10-31 北京福元医药股份有限公司 乙氨基取代的三环杂环化合物及其组合物、制剂和用途
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
AU2024359022A1 (en) * 2023-10-10 2026-04-09 Jazz Pharmaceuticals Research Uk Limited Cannabinoid compounds and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2641099A (en) * 1998-02-27 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
WO2004003152A2 (en) 2002-06-26 2004-01-08 Chiron Corporation Sos1 inhibitors
US20070065622A1 (en) 2005-09-22 2007-03-22 Scientific Technologies Incorporated Safety Mat Active Joining Trim
WO2011075517A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US10087215B2 (en) * 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
WO2016077793A1 (en) 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CA3014192A1 (en) 2016-02-12 2017-08-17 Forma Therapeutics, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
US10898487B2 (en) * 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
ES2944306T3 (es) 2017-12-21 2023-06-20 Boehringer Ingelheim Int Piridopirimidinonas sustituidas por bencilamino y derivados como inhibidores de SOS1
CA3097231A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用

Also Published As

Publication number Publication date
US12435066B2 (en) 2025-10-07
JP2023504113A (ja) 2023-02-01
PL4065575T3 (pl) 2024-06-24
AU2020393205A1 (en) 2022-06-30
CA3154914A1 (en) 2021-06-03
CL2022001392A1 (es) 2023-03-17
EP4065575B1 (en) 2024-01-31
BR112022010383A2 (pt) 2022-08-23
ZA202206253B (en) 2023-01-25
MX2022006475A (es) 2022-09-07
PH12022551014A1 (en) 2023-03-13
CN114746411A (zh) 2022-07-12
FI4065575T3 (fi) 2024-05-02
RS65526B1 (sr) 2024-06-28
SMT202400273T1 (it) 2024-09-16
PE20221336A1 (es) 2022-09-13
WO2021105960A1 (en) 2021-06-03
LT4065575T (lt) 2024-05-27
SI4065575T1 (sl) 2024-06-28
EP4065575A1 (en) 2022-10-05
HUE066732T2 (hu) 2024-09-28
HRP20240547T1 (hr) 2024-07-05
JP7629922B2 (ja) 2025-02-14
CO2022008997A2 (es) 2022-07-19
ES2982576T3 (es) 2024-10-16
DK4065575T3 (da) 2024-04-15
US20230013778A1 (en) 2023-01-19
PT4065575T (pt) 2024-05-03
CN114746411B (zh) 2024-06-25
IL292721A (en) 2022-07-01
KR20220110241A (ko) 2022-08-05
CR20220312A (es) 2022-08-05

Similar Documents

Publication Publication Date Title
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
ECSP22058816A (es) Compuestos tric?clicos sustituidos
DOP2022000194A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
PE20200341A1 (es) Composiciones y compuestos terapeuticos y metodos para utilizarlos
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
MX2025002817A (es) Compuestos para el tratamiento del cancer
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
DOP2022000075A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CU20190095A7 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CU20220023A7 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR133167A1 (es) Macrociclos para el tratamiento de enfermedad autoinmunitaria
CL2024001524A1 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
AR124698A1 (es) Derivados tricíclicos útiles como inhibidores de parp7